Docetaxel Plus Gemcitabine Promising in Advanced Pancreatic Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 11
Volume 11
Issue 11

ORLANDO-In a randomized multicenter phase II study of advanced pancreatic carcinoma by the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Group, the combination of docetaxel (Taxotere) and gemcitabine (Gemzar) was "promising" relative to docetaxel/cisplatin (Platinol), Manfred P. Lutz, MD, of University Hospital, Ulm, Germany, said at the 38th Annual Meeting of the American Society of Clinical Oncology (abstract 498).

ORLANDO—In a randomized multicenter phase II study of advanced pancreatic carcinoma by the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Group, the combination of docetaxel (Taxotere) and gemcitabine (Gemzar) was "promising" relative to docetaxel/cisplatin (Platinol), Manfred P. Lutz, MD, of University Hospital, Ulm, Germany, said at the 38th Annual Meeting of the American Society of Clinical Oncology (abstract 498).

"Both combinations are active in advanced pancreatic cancer, and both have acceptable toxicities," Dr. Lutz said.

Although gemcitabine is widely used for the treatment of advanced pancreatic cancer, he said, response rates when used as a single agent are less than 10%, and median survival is less than 6 months. Both docetaxel and cisplatin also have proven clinical activity in this disease and are synergistic with gemcitabine in peclinical models.

The trial enrolled 96 patients at 17 centers. Patients received gemcitabine 800 mg/m2 on days l and 8 and docetaxel 85 mg/m2 on day 8, every 21 days, or docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1, every 21 days.

The most important toxicity was neutropenia, which occurred in approximately 30% of patients. Febrile neutropenia was seen in 17% of patients on docetaxel/cisplatin and 7% on docetaxel/gemcitabine. There was more neuropathy and vomiting in the docetaxel/cisplatin arm.

Partial responses were confirmed in 6 of 38 evaluable patients in the docetaxel/gemcitabine arm (15.8%) and in 5 of 31 evaluable patients in the docetaxel/cisplatin arm (16.1%). Progression-free survival was 3.6 months with gemcitabine and 2.8 months with cisplatin. Median survival (intent to treat) was 7.4 months and 6.3 months, respectively. "One-year survival is roughly 30% for gemcitabine/docetaxel," Dr. Lutz said.

He noted that toxicity in both arms is predictable and manageable. "However," he said, "gemcitabine/docetaxel seems to have the favorable toxicity profile." The docetaxel/gemcitabine combination will be tested against gemcitabine alone in a randomized phase III trial.  

Related Videos
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content